Skip to main content
. 2019 Oct 10;134(5):899–908. doi: 10.1097/AOG.0000000000003500

Fig. 2. Percentage of sexual encounters that were satisfying sexual events (modified intent-to-treat populations, post hoc analysis). No significant difference between treatment groups was observed for satisfying sexual events associated with study drug and reported within 72 hours.

Fig. 2.

Kingsberg. Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019.